利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.02 秒)

    Novel antibody structures derived from human germline sequences
    2.
    发明申请
    Novel antibody structures derived from human germline sequences 审中-公开
    衍生自人种系序列的新型抗体结构

    公开(公告)号：US20130267688A1

    公开(公告)日：2013-10-10

    申请号：US13327752

    申请日：2012-02-21

    申请人： Li-Te Chin ,  Chishih Chu ,  Shu Ching Hsu

    发明人： Li-Te Chin ,  Chishih Chu ,  Shu Ching Hsu

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2818 ,  C07K2317/21

    摘要： In order to provide necessary information for the production of complete human monoclonal antibodies capable of human CD152 (CTLA-4) binding, the primary structures of heavy and light chains have been elucidated. The novel amino acid sequence of identified heavy and light chains are derived from VH3 and Vλ germline genes, respectively. Antibodies comprising such novel structures cause specific binding to soluble recombinant human CD152 as well as to activated human peripheral T cells, where the expression of CD152 has been elevated.

    摘要翻译： 为了提供生产能够进行人CD152（CTLA-4）结合的完整人单克隆抗体的必要信息，已经阐明了重链和轻链的一级结构。 鉴定的重链和轻链的新氨基酸序列分别衍生自VH3和Vlambda种系基因。 包含这种新型结构的抗体引起与可溶性重组人CD152的特异性结合以及CD152的表达升高的活化的人外周T细胞。

    Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes
    3.
    发明授权
    Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes 有权
    通过人淋巴细胞的定点体外免疫产生人自身抗体的方法

    公开(公告)号：US08021860B2

    公开(公告)日：2011-09-20

    申请号：US12318679

    申请日：2009-01-06

    申请人： Li-Te Chin ,  Shu-Ching Hsu

    发明人： Li-Te Chin ,  Shu-Ching Hsu

    IPC分类号： C12P21/04

    CPC分类号： G01N33/5052 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/2818 ,  C07K2317/73 ,  C07K2317/74 ,  G01N33/505 ,  G01N33/6854 ,  G01N2333/70521

    摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

    摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。

    Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist
    4.
    发明申请
    Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist 有权
    用于产生具有激动剂，拮抗剂或反向激动剂的性质的人抗体的方法

    公开(公告)号：US20090286224A1

    公开(公告)日：2009-11-19

    申请号：US12318679

    申请日：2009-01-06

    申请人： Li-Te Chin ,  Shu-Ching Hsu

    发明人： Li-Te Chin ,  Shu-Ching Hsu

    IPC分类号： C12Q1/70 ,  G01N33/53 ,  C07K7/00 ,  C07K16/28

    CPC分类号： G01N33/5052 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/2818 ,  C07K2317/73 ,  C07K2317/74 ,  G01N33/505 ,  G01N33/6854 ,  G01N2333/70521

    摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

    摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。

    Method of isolating regulatory T cells from human samples
    7.
    发明授权
    Method of isolating regulatory T cells from human samples 有权
    从人类样品中分离调节性T细胞的方法

    公开(公告)号：US07968300B2

    公开(公告)日：2011-06-28

    申请号：US11943682

    申请日：2007-11-21

    申请人： Li-Te Chin ,  Shu-Ching Hsu

    发明人： Li-Te Chin ,  Shu-Ching Hsu

    IPC分类号： G01N33/53

    CPC分类号： A61K35/26 ,  A61K38/17 ,  C07K16/2818 ,  C07K2317/34 ,  C07K2317/92 ,  G01N33/505

    摘要： The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.

    摘要翻译： 本发明提供了完全人抗体性质的CTLA-4非阻断剂，因此在人体中是非免疫原性的。 使用这种非阻断剂的免疫测定方法测量人受试者样品中的CTLA-4含量。 本发明还提供了一种分离人类调节性T细胞的新方法。 所产生的富含和贫化的细胞群可用于治疗或改善人类疾病。

    Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist
    8.
    发明授权
    Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist 有权
    用于产生具有激动剂，拮抗剂或反向激动剂的性质的人抗体的方法

    公开(公告)号：US08158386B2

    公开(公告)日：2012-04-17

    申请号：US12888713

    申请日：2010-09-23

    申请人： Li-Te Chin ,  Shu-Ching Hsu

    发明人： Li-Te Chin ,  Shu-Ching Hsu

    IPC分类号： G01N33/567

    CPC分类号： G01N33/5052 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/2818 ,  C07K2317/73 ,  C07K2317/74 ,  G01N33/505 ,  G01N33/6854 ,  G01N2333/70521

    摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

    摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。

    Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
    9.
    发明授权
    Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist 有权
    用激活剂，拮抗剂或反向激动剂的性质产生人CD152的人抗体的方法

    公开(公告)号：US07494779B2

    公开(公告)日：2009-02-24

    申请号：US10866120

    申请日：2004-06-14

    申请人： Li-Te Chin ,  Shu-Ching Hsu

    发明人： Li-Te Chin ,  Shu-Ching Hsu

    IPC分类号： G01N33/53

    CPC分类号： G01N33/5052 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/2818 ,  C07K2317/73 ,  C07K2317/74 ,  G01N33/505 ,  G01N33/6854 ,  G01N2333/70521

    摘要： A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

    摘要翻译： 公开了一种获得给定生理受体的激动剂，拮抗剂和反向激动剂的方法。 对于该方法，使用计算机设计合成免疫原，其在体外对人类含淋巴细胞的细胞群体起作用。 优选的受体是人CD152，特别是分别引发作为拮抗剂，反向激动剂和激动剂的抗体的CDR1，CDR2和CDR3的区域。 还提供了治疗人外周淋巴细胞用于筛选产生药理作用的CD152配体的方法。